Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00495599
Status:
COMPLETED
Last Update Posted:
2016-11-21
First Post:
2007-07-02
Brief Title:
Adipose Secretory Function in Patients Before After Laparoscopic Surgery
Sponsor:
Vanderbilt University
Organization:
Vanderbilt University
Study Overview
Official Title:
Adipose Secretory Function in Patients Before After Laparoscopic Surgery
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The central hypothesis of our study is that metabolic and hemodynamic improvements following gastric bypass surgery are mediated by downregulation of inflammation-related adipokines produced by the intra-abdominal adipose tissue such as Visfatin
Detailed Description:
Central obesity represents a major risk for the development of type 2 diabetes and cardiovascular complications Obesity is often associated with insulin resistance and abnormal production of inflammatory cytokines Adipose tissue and especially omentum adipocytes and resident macrophages release several cytokines Visfatin corresponds to a protein identified previously as pre-B cell colony-enhancing factor PBEF a 52-kilodalton cytokine expressed in lymphocytes 1 Visfatin exerted insulin-mimetic effects in cultured cells and lowered plasma glucose levels in mice Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild-type littermates Surprisingly visfatin binds to and activates the insulin receptor
Adipose tissue protein and mRNA expression of Visfatin PBEF has not been investigated in a single study design with regard to the relationship to fat distribution insulin resistance and other metabolic risk factors especially in morbidly obese individual undergoing weight loss surgery Therefore we propose the following specific aims Investigate the protein and mRNA expression of Visfatin PBEF in the peripheral subcutaneous and visceral omentum adipose tissues of morbidly obese subjects and their relationships to the changes in body composition fat distribution insulin sensitivity and time-dependent reversal of co-morbidities following gastric bypass surgery
Adipose tissue protein and mRNA expression of Visfatin PBEF has not been investigated in a single study design with regard to the relationship to fat distribution insulin resistance and other metabolic risk factors especially in morbidly obese individual undergoing weight loss surgery Therefore we propose the following specific aims Investigate the protein and mRNA expression of Visfatin PBEF in the peripheral subcutaneous and visceral omentum adipose tissues of morbidly obese subjects and their relationships to the changes in body composition fat distribution insulin sensitivity and time-dependent reversal of co-morbidities following gastric bypass surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None